Post by Lonza

Gene therapies are rapidly advancing but delivering them effectively remains a critical challenge. In a recent article published in Biocompare, Lonza Specialized Modalities experts explore how optimizing lentiviral vector (LVV) development is essential to enabling the next generation of in vivo gene therapies and they highlight: • Growing market demand for robust, scalable LVV manufacturing • Complexity of ensuring purity, stability, and potency, particularly as the industry shifts toward in vivo applications with more stringent requirements • How emerging technologies, such as advanced analytical methods and improved purification approaches, are helping overcome longstanding development and manufacturing challenges Read the full article: https://ow.ly/Gtqt50ZgbVI #Lonza #CDMO #CellAndGeneTherapy